二仙汤联合依降钙素治疗绝经期妇女骨质疏松症临床的研究.docVIP

二仙汤联合依降钙素治疗绝经期妇女骨质疏松症临床的研究 　　摘要：目的 观察二仙汤联合依降钙素治疗绝经期妇女骨质疏松症的临床疗效。方法 将女性绝经期骨质疏松症患者80例随机分为治疗组和对照组各40例，对照组予肌内注射依降钙素，治疗组在对照组治疗基础上口服二仙汤，2组均用药12周。观察2组患者治疗前后主要临床症状积分、视觉模拟量表（VAS）评分、L2～L4及胫骨的骨密度，评定治疗效果。结果 2组治疗后VAS评分明显降低（P0.05）；治疗组总有效率为92.5%（37/40），对照组为75.0%（30/40），组间比较差异有统计学意义（P0.05）；2组治疗后主要症状积分比较差异有统计学意义（P0.05），治疗组在改善患者躯体症状方面明显优于对照组；2组治疗后L2～L4骨密度总体呈升高趋势，治疗组骨密度高于对照组。结论 二仙汤联合依降钙素治疗绝经期妇女骨质疏松症，在改善临床症状及升高骨密度方面效果显著。 　　关键词：骨质疏松症；二仙汤；依降钙素；绝经期妇女 　　DOI：10.3969/j.issn.1005-5304.2016.06.007 　　中图分类号：R274.915.5 文献标识码：A 文章编号：1005-5304（2016）06-0023-04 　　Abstract： Objective To observe the clinical efficacy of Erxian Decoction combined with elcatonin for the treatment of postmenopausal osteoporosis. Methods Eighty cases of female patients with postmenopausal osteoporosis were randomly divided into treatment group and control group， 40 cases in each group. The control group received intramuscular injections elcatonin treatment， and the treatment group received oral Erxian Decoction on the basis of the treatment of the control group， for 12 weeks. The main clinical symptom score， VAS score and bone mineral density （BMD） of L2-L4 and in the tibia of the two groups were observed before and after treatment to assess the therapeutic effect. Results After treatment， VAS scores of the two groups were significantly lower （P0.05）. The total effective rate of the treatment group was 92.5% （37/40）； the control group was 75.0 （30/40）， with statistical significance （P0.05）. The treatment group was significantly better than the control group in main symptom scores， especially in improving body symptoms （P0.05）. BMD of the treatment group was significantly higher than the control group. Conclusion Erxian Decoction combined with elcatonin therapy for postmenopausal women with osteoporosis can significantly improve clinical symptoms and increase BMD. 　　Key words： osteoporosis； Erxian Decoction； elcatonin； menopausal women 　　绝经期骨质疏松症是指妇女绝经后由于短时间内雌激素水平急剧下降，导致骨吸收亢进，全身骨量减少，骨骼脆性增加，极易发生骨折的一种与绝经有关的代谢性骨病，属原发性骨